

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Oventus Medical Limited
ABN	12 608 393 282

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Melvyn John Bridges
Date of last notice	2 September 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Interests held by: Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust Parma Corporation Pty Ltd Lucille Bridges (spouse) Adinbri Super Pty Ltd atf The Bridges Super Fund
Date of change	9 December 2019

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>Direct: 75,367 Ordinary Shares; & 200,732 Options exercisable at \$0.578 ea; expiring 23 February 2021 Indirect – interests held by Parma Corporation Pty Ltd 1,470,245 Ordinary Shares Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 467,685 Ordinary Shares Indirect – interests held by Adinbri Super Pty Ltd as trustee for the Bridges Super Fund 703,069 Ordinary Shares Indirect – Lucille Bridges (spouse) 138,429 Ordinary Shares</p>
<p>Class</p>	<p>Options</p>
<p>Number acquired</p>	<p>Direct – 50,000 Options</p>
<p>Number disposed</p>	<p>Nil</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Direct – 50,000 Options Nil; approved at the Annual General Meeting held on 22 November 2019</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<p>Direct: 75,367 Ordinary Shares; & 200,732 Options exercisable at \$0.578 ea, expiring 23 February 2021; & 50,000 Options at \$0.4228 ea, expiring 8 December 2024</p> <p>Indirect – interests held by Parma Corporation Pty Ltd 1,470,245 Ordinary Shares</p> <p>Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 467,685 Ordinary Shares</p> <p>Indirect – interests held by Adinbri Super Pty Ltd as trustee for the Bridges Super Fund 703,069 Ordinary Shares</p> <p>Indirect – Lucille Bridges (spouse) 138,429 Ordinary Shares</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Options – issued under the Oventus Executive Option Plan as approved at the Annual General Meeting held on 22 November 2019

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.